Orthopedics
Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
January 25, 2011 7:31 am | by Bio-Medicine.Org | News | CommentsNEW YORK, Jan. 25, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers...
R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia
January 24, 2011 1:34 am | by Bio-Medicine.Org | News | CommentsTOKYO, Jan. 24, 2011 /- R-Tech Ueno, Ltd. is pleased to announce that the Phase 2a clinical study of RK-023 to treat androgenetic alopecia (note 1) was completed by January 21, 2011. Our company focuses on the area of no topical prescription drug in the market of androgenetic alopecia...
Novel Night Time Healing is Key to Shoulder Pain Relief From ROTATORELIEVER
January 24, 2011 1:34 am | by Bio-Medicine.Org | News | CommentsTRAVERSE CITY, Mich., Jan. 24, 2011 /- A good night's sleep and just five minutes of daily exercise are keys to reversing the debilitating cycle of shoulder pain. That's the prescription of Dr. Michael Carroll, M.D., inventor of ROTATORELIEVER ( www.rotatoreliever.com ), a patent-pending...
'Hot Health Topics' program hits airwaves(3)
January 21, 2011 2:39 pm | by Arizona State University | News | CommentsTune in each week to KFNX-AM, starting Jan. 24., for the College of Nursing & Health Innovation's "Hot Health Topics," its first radio program.read more
Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardio...
January 20, 2011 5:44 am | by Bio-Medicine.Org | News | CommentsCAMBRIDGE, Mass., Jan. 20, 2011 /- Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease...
Software Quantifies Leaf Vein Networks, Enables Plant Biology Advances
January 13, 2011 10:38 am | by Georgia Tech Institute of Technology | News | CommentsBy studying a plant's vein network pattern, biologists can investigate the plant's response to changing environments. To quickly examine leaves, researchers developed software that extracts information about macroscopic vein structures directly from leaf images.
Stereotaxis Announces CE Mark and First Human Case for Vdriveâ„¢(2)
January 11, 2011 3:37 am | by Bio-Medicine.Org | News | CommentsST. LOUIS, Jan. 11, 2011 /- Stereotaxis, Inc. (Nasdaq: STXS ) announces the first successful cardiac ablation procedure with the Vdrive™ robotic navigation system as the company received CE Mark for this latest innovation. In the first procedure with the Vdrive system,...
Study: Many ICD Patients Don & #8217;t Meet the Guidelines
January 7, 2011 12:36 pm | by U.S. Food & Drug Administration | News | CommentsNearly 25 percent of patients who receive implantable cardioverter-defibrillators (ICDs) for primary prevention don’t meet the evidence-based criteria, a new study published in the Journal of the American Medical Association (JAMA) says.
Century Park Capital Partners Announces the Recapitalization of Cirtec Medical Systems, LLC(2)
January 6, 2011 7:37 am | by Bio-Medicine.Org | News | CommentsLOS ANGELES, Jan. 6, 2011 /- Century Park Capital Partners is pleased to announce that it led the recapitalization of Cirtec Medical Systems, LLC ("Cirtec") along with Charter Oak Equity and the company's founders. Cirtec is a leading provider of client focused, comprehensive medical...
New CVS Caremark Study Finds Health Information Technology May Help Promote Adherence, But More Information and Direction Needed
December 23, 2010 7:31 am | by Bio-Medicine.Org | News | CommentsWOONSOCKET, R.I., Dec. 23, 2010 /- A new study that reviews more than four decades of medical journal articles about the impact of health information technology (HIT) and electronic communications on medication adherence concludes that while there is evidence to suggest that simple...
Scott & White Finalizes College Station Land Deal
December 22, 2010 7:31 am | by Bio-Medicine.Org | News | CommentsCOLLEGE STATION, Texas, Dec. 22, 2010 /- Scott & White Healthcare has acquired approximately 98 acres of undeveloped land that will be the home for a new 143-bed acute care hospital project. The property was purchased from Weingarten Realty Investors and College Station ISD. The...
Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences
December 21, 2010 7:35 am | by Bio-Medicine.Org | News | CommentsMOUNTAIN VIEW, Calif., Dec. 21, 2010 /- Based on its recent analysis of the surface functionalization technologies market, Frost & Sullivan recognizes Cambridge, Mass.-based Semprus BioSciences with the 2010 Enabling Technology of the Year Award for Surface Functionalization...
MinuteClinic Becomes First Retail Clinic Provider to Launch Partnership with National Patient Safety Foundation for Ask Me 3â„¢ Program
December 20, 2010 8:33 am | by Bio-Medicine.Org | News | CommentsWOONSOCKET, R.I., Dec. 20, 2010 /- MinuteClinic, the pioneer and largest provider of retail-based medical clinics in the United States, has entered into an agreement with the National Patient Safety Foundation to become the nation's first retail clinic provider to implement the Ask Me 3...
Boston researchers test treatment for autism link
December 17, 2010 9:32 am | by Mass High Tech: The Journal of New England Technology | News | CommentsChildren's Hospital Boston scientists have initiated a three-year clinical trial to test a potential treatment for Rett Syndrome, known to cause autism in girls.
First NxStage® Home Hemodialysis Patients Celebrate Seven-Year Anniversary
December 16, 2010 4:32 am | by Bio-Medicine.Org | News | CommentsLAWRENCE, Mass., Dec. 16, 2010 /- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of innovative dialysis products, today announced that a group of its first patients are celebrating their seven-year anniversary of home hemodialysis treatment with the NxStage® System...
New Topical Research Reports by iData Research Published by MarketPublishers.com
December 16, 2010 4:32 am | by Bio-Medicine.Org | News | CommentsLONDON, Dec. 16, 2010 /- Market Publishers Ltd informs that new in-demand market research reports by iData Research have been added to its catalogue. Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 . In 2010, the Asia Pacific markets for...
New Study Classifies and Analyzes Protein-Protein Interfaces
December 15, 2010 7:33 am | by Georgia Tech Institute of Technology | News | CommentsA new study published this week suggests that there may be roughly a thousand structurally-distinct protein-protein interfaces -- and that their structures depend largely on the simple physics of the proteins.
Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
December 15, 2010 4:32 am | by Bio-Medicine.Org | News | CommentsEMERYVILLE, Calif., Dec. 15, 2010 /- Bionovo, Inc. (Nasdaq: BNVI ) today announced the publication of a study entitled "CC3/TIP30 regulates metabolic adaptation of tumor cells to glucose limitation" in the journal Cell Cycle . The study describes the critical linkage between the...
Lanx, Inc. Appoints Dan Gladney Chief Executive Officer
December 15, 2010 4:31 am | by Bio-Medicine.Org | News | CommentsBROOMFIELD, Colo., Dec. 15, 2010 /- Lanx, Inc., a privately held medical device company focused on developing and commercializing innovative devices for spinal surgery, announced the appointment of Dan W. Gladney as Chief Executive Officer and as a member of the Board of Directors. He...
NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study
December 10, 2010 4:33 am | by Bio-Medicine.Org | News | CommentsSANTA CLARA, Calif., Dec. 10, 2010 /- NewCardio, Inc., (OTC Bulletin Board: NWCI ) a cardiovascular diagnostic solutions developer, today presented the results from a blinded drug safety study conducted by the Cardiac Safety Research Consortium (CSRC) to evaluate the performance of...
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
December 10, 2010 4:33 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Dec. 10, 2010 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial...
HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
December 10, 2010 4:32 am | by Bio-Medicine.Org | News | CommentsFRAMINGHAM, Mass. and SYDNEY, Dec. 10, 2010 /- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of $125 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf...
Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
December 9, 2010 7:33 am | by Bio-Medicine.Org | News | CommentsEAST HANOVER, N.J., Dec. 9, 2010 /- A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been...
Anthera Announces Update Call Regarding Vial Problems
December 9, 2010 7:32 am | by Bio-Medicine.Org | News | CommentsHAYWARD, Calif., Dec. 9, 2010 /- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to provide an update on the ongoing investigation and...
Aromatase Inhibitors Increased Risk of Heart Disease in Postmenopausal Women with Breast Cancer
December 9, 2010 5:34 am | by AACR | News | CommentsSAN ANTONIO - Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.
